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The HIV/AIDS pandemic has claimed the lives 
of over 30 million people. Although antiretro-
viral drugs can control the progression of AIDS 
(Louie et al., 2003; Hofman and Nelson, 2006), 
they are not in general use in the developing 
world. As a completely protective vaccine against 
HIV-1 has not yet been found, prevention and 
treatment options involving delivery of broadly 
neutralizing antibodies (bNAbs) identified in a 
minority of HIV-infected individuals are being 
considered (Johnson et al., 2009; Balazs et al., 
2012). bNAbs that target conserved epitopes on 
the HIV-1 envelope spike can prevent infection 
in animal models (Baba et al., 2000; Mascola et al., 
2000; Hessell et al., 2009; Johnson et al., 2009; 
Balazs et al., 2012), delay rebound of HIV-1 after 
cessation of antiretroviral drugs (Trkola et al., 
2005; Mehandru et al., 2007), and treat an ongo-
ing infection (Klein et al., 2012).
NIH45-46, isolated in a screen that yielded 
>500 HIV-1 antibodies using single cell cloning 
techniques (Scheid et al., 2009, 2011), is a more 
potent clonal variant of VRC01, a bNAb di-
rected against the CD4 binding site (CD4bs) 
of gp120 (Wu et al., 2010; Zhou et al., 2010). 
Enhancing the efficacy of bNAbs, and in particu-
lar, designing bNAbs that retain potency against 
escape mutants selected during exposure to bNAbs, 
would facilitate their use as therapeutics. We 
previously used structure-based design to create 
CORRESPONDENCE  
Ron Diskin:  
ron.diskin@weizmann.ac.il
Abbreviations used: bNAb, 
broadly neutralizing antibody; 
CD4bs, CD4 binding site;  
HC, heavy chain; LC, light 
chain; SPR, surface  
plasmon resonance.
F. Klein, J.A. Horwitz, A. Halper-Stromberg, and D. Noah 
Sather contributed equally to this paper.
R. Diskin’s present address is Dept. of Structural Biology, 
Weizmann Institute of Science, Rehovot 76100, Israel.
Restricting HIV-1 pathways for escape using 
rationally designed anti–HIV-1 antibodies
Ron Diskin,1 Florian Klein,2 Joshua A. Horwitz,2 Ariel Halper-Stromberg,2 
D. Noah Sather,3 Paola M. Marcovecchio,1 Terri Lee,1 Anthony P. West Jr.,1 
Han Gao,1 Michael S. Seaman,4 Leonidas Stamatatos,3,5  
Michel C. Nussenzweig,2,6 and Pamela J. Bjorkman1,6
1Division of Biology, California Institute of Technology, Pasadena, CA 91125
2Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065
3Seattle Biomedical Research Institute, Seattle, WA 98109
4Beth Israel Deaconess Medical Center, Boston, MA 02215
5Department of Global Health, University of Washington, Seattle, WA 98109
6Howard Hughes Medical Institute, Chevy Chase, MD 20815
Recently identified broadly neutralizing antibodies (bNAbs) that potently neutralize most HIV-1  
strains are key to potential antibody-based therapeutic approaches to combat HIV/AIDS in  
the absence of an effective vaccine. Increasing bNAb potencies and resistance to common 
routes of HIV-1 escape through mutation would facilitate their use as therapeutics. We previ-
ously used structure-based design to create the bNAb NIH45-46G54W, which exhibits superior 
potency and/or breadth compared with other bNAbs. We report new, more effective NIH45-
46G54W variants designed using analyses of the NIH45-46–gp120 complex structure and 
sequences of NIH45-46G54W–resistant HIV-1 strains. One variant, 45-46m2, neutralizes 96% 
of HIV-1 strains in a cross-clade panel and viruses isolated from an HIV-infected individual 
that are resistant to all other known bNAbs, making it the single most broad and potent anti–
HIV-1 antibody to date. A description of its mechanism is presented based on a 45-46m2–
gp120 crystal structure. A second variant, 45-46m7, designed to thwart HIV-1 resistance to 
NIH45-46G54W arising from mutations in a gp120 consensus sequence, targets a common route 
of HIV-1 escape. In combination, 45-46m2 and 45-46m7 reduce the possible routes for the 
evolution of fit viral escape mutants in HIV-1YU-2–infected humanized mice, with viremic 
control exhibited when a third antibody, 10–1074, was added to the combination.
© 2013 Diskin et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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which normally accommodates Phe43CD4 of CD4 (Kwong 
et al., 1998), thereby enhancing both binding and neutral-
ization (Diskin et al., 2011). Because HIV-1 infection usually 
emerges from a single viral strain (Keele et al., 2008), the abil-
ity of NIH45-46G54W to neutralize transmitted founder strains 
and its high potency (Diskin et al., 2011) makes it a promising 
candidate for preventing infection via passive delivery (Baba 
et al., 2000; Mascola et al., 2000; Trkola et al., 2008; Hessell 
NIH45-46G54W, a single amino acid change from NIH45-46, 
which was the single most potent and broadly neutralizing anti–
HIV-1 antibody described to date (Diskin et al., 2011; Sather 
et al., 2012; Nakamura et al., 2013). It belongs to the PVL 
(potent VRC01-like) family of antibodies that target the CD4bs 
on the HIV-1 trimeric spike complex (West et al., 2012). The 
G54W substitution allows NIH45-46G54W to use a conserved 
hydrophobic pocket on the surface of gp120, the Phe43 pocket, 
Figure 1. Comparison of neutralization potencies  
of 45-46m bNAb mutants. (A) Summary of 45-46m mutants.  
(B) Coverage curves showing the cumulative frequency of IC50 
values up to the concentration shown on the x axis (plot of the 
percent of viral strains [y axis] from a panel of 118 strains that 
were neutralized at a given IC50 cutoff [x axis]). A vertical line at 
0.1 µg/ml designates a theoretical desired potency for a thera-
peutic reagent. (C) Table showing IC50 values (µg/ml) for NIH45-
46, NIH45-46G54W, 45-46m2, and 45-46m7 against 28 strains 
that are resistant to or poorly neutralized by NIH45-46. Strains 
marked in blue have an altered N/DNGG motif. IC50s were de-
rived from curves generated from data points obtained in dupli-
cate or triplicate.
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et al., 2009; Johnson et al., 2009; Balazs et al., 2012) or topical 
microbicide (Veazey et al., 2003; Denton et al., 2008) approaches. 
However, a small group of HIV-1 clones are naturally resistant 
to neutralization by NIH45-46G54W (Diskin et al., 2011) and 
escape mutants emerge during exposure to NIH45-46G54W 
(Klein et al., 2012). Here, we illustrate a mechanism by which 
the breadth of NIH45-46G54W can be increased via extending 
contacts with gp120 and substitutions to render it less sensi-
tive to likely escape mutants within a consensus signature es-
cape motif on gp120.
RESULTS
Increasing the potency of NIH45-46G54W
We previously postulated that neutralization of an NIH45-46–
resistant virus by a chimera of the NIH45-46 heavy chain (HC) 
paired with the VRC01 light chain (LC) was achieved via addi-
tional contacts that Tyr28VRC01(LC), but not Ser28NIH45-46(LC), 
makes with an N-linked glycan attached to Asn276gp120 (Diskin 
et al., 2011) that is predicted to be present in 94.7% of 4279 Env 
sequences in the Los Alamos HIV Sequence Database (www.
hiv.lanl.gov/). In an effort to increase the breadth of NIH45-
46G54W, we introduced an S28Y substitution into the NIH45-46 
LC. We expressed NIH45-46G54W(HC), S28Y(LC) (hereafter referred 
to as 45-46m2; Fig. 1 A) and evaluated it using in vitro neutral-
ization assays against a cross-clade panel of 118 primary HIV-1 
isolates including transmitted founder viruses (Tables S1 and S2). 
Against this panel, 45-46m2 was as potent as NIH45-46G54W 
(geometric mean IC50 values of 0.028 and 0.030 µg/ml for 
45-46m2 and NIH45-46G54W, respectively) but exhibited in-
creased breadth (Fig. 1 B), neutralizing up to 96% of strains. Of 
Figure 2. Neutralization of highly resistant viral clones from patient VC10042. (A) Neutralization curves for NIH45-46G54W, 45-46m2, and  
45-46m7 against 10 viral clones from patient VC10042 that were isolated 19 yr (first three panels) or 22 yr (remaining panels) after infection. (B) Scatter 
plot comparing IC50 values (µg/ml) for VRC01, NIH45-46G54W, 45-46m2, and 45-46m7 against viral clones from patient VC10042. Despite their breadth, 
45-46m2 and 45-46m7 did not neutralize SIV strains (SIVmac251 and SIVsmE660; not depicted). (C) IC50 values (µg/ml) for NIH45-46G54W, 45-46m2, and 
45-46m7 against viral clones from patient VC10042. The reported IC50 values represent the mean of two independent experiments, each with two 
replicates. Significance of statistical differences: * (VRC01 and 45-46m2), P < 0.0001; ** (NIH45-46G54W and 45-46m2), P = 0.0033; *** (45-46m2 and  
45-46m7), P = 0.0274. Error bars represent standard deviation from the mean.
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Fab bound to 93TH057 gp120 (Fig. 3 A and Table S3) and 
compared it with the structure of NIH45-46 bound to the same 
gp120 (Diskin et al., 2011). The total buried surface area of the 
45-46m2/gp120 complex (3214 Å2) was larger than the bur-
ied surface area calculated for NIH45-46/gp120 (2636 Å2) or 
NIH45-46G54W/gp120 (2869 Å2; Fig. 3 B). Consistent with this 
observation, surface plasmon resonance (SPR) binding assays 
(Fig. 4 A) demonstrated that 45-46m2 Fab exhibited a higher 
affinity and slower dissociation rate than NIH45-46G54W Fab or 
NIH45-46 Fab for binding 93TH057 gp120 (Fig. 4 B). The 
increased buried surface area for the 45-46m2–gp120 com-
plex largely resulted from the predicted (Diskin et al., 2011) 
penetration of Trp5445-46m2 into the Phe43CD4 pocket of gp120 
(Fig. 3 C). Local rearrangements in the surrounding residues of 
the gp120 Phe43CD4 pocket occurred; Gly473gp120 was shifted 
by 4Å (C-C distance) toward Trp5445-46m2 due to a hy-
drogen bond between its carbonyl oxygen and the -nitrogen 
of Trp5445-46m2, and Ile371gp120 adopted a different rotamer to 
accommodate Trp5445-46m2 (Fig. 3 C). The Gly–Trp substitu-
tion at position 54 allowed the tryptophan indole side chain to 
bury an additional 233 Å2 (144 Å2 on 45-46m2 and 89 Å2 on 
gp120) of surface area in the Fab–gp120 complex, representing 
28 strains that were either poorly neutralized (IC50 ≥ 1.0 µg/ml) 
or NIH45-46 resistant (IC50 > 50 µg/ml), 45-46m2 had a geo-
metric mean IC50 of 0.35 µg/ml compared with geometric means 
of 1.84 µg/ml (NIH45-46G54W) and 14.51 µg/ml (NIH45-46; 
calculated with IC50s > 50 µg/ml input as 50 µg/ml; Fig. 1 C).
We next compared the neutralizing activity of NIH45-
46G54W and 45-46m2 using viruses from an elite neutralizer, pa-
tient VC10042, who developed unusually broad and potent 
cross-neutralizing antibody responses but whose circulating 
viruses evolved to escape their action; thus, with few exceptions, 
the viral clones isolated from VC10042 were highly resistant 
to known bNAbs, especially CD4bs antibodies (Sather et al., 
2012). Only one viral clone isolated from VC10042 was sus-
ceptible to VRC01, but the majority (8 of 12) were moderately 
susceptible to NIH-45-46G54W (Sather et al., 2012). In contrast, 
NIH45-46m2 neutralized all (12 of 12) of the viral clones with 
up to 10-fold greater potency relative to NIH45-46G54W when 
evaluated against NIH45-46G54W-sensitive clones (Fig. 2).
Structural mechanism for the increased potency of 45-46m2
To explore the mechanism underlying the increased breadth of 
45-46m2, we solved the 2.8 Å crystal structure of the 45-46m2 
Figure 3. 45-46m2–gp120 complex structure. (A) 45-46m2/gp120 structure with gp120 as a gray surface and 45-46m2 Fab in cyan (HC) and blue 
(LC) C traces. Ordered N-glycans are shown in van der Waals representation, with the Asn276gp120–linked N-glycan highlighted in shades of red. The loca-
tions of Tyr2845-46m2(LC) and Trp5445-46m2(HC) are indicated by arrows. (B) Buried surface areas between gp120 and the indicated antibodies. The buried surface 
area for NIH45-46G54W was calculated by adding the contribution of Trp54 (derived from the structure of 45-46m2/gp120) to the buried surface area calcu-
lated from the NIH45-46/gp120 structure. (C) Close-up comparison of the interactions of Trp5445-46m2 (cyan side chain) and Gly54NIH45-46 (magenta) with 
gp120 in the structures of 45-46m2/gp120 (gray) and NIH45-46/gp120 (magenta). A hydrogen bond (green dashed line) between the nitrogen atom of the 
Trp5445-46m2 indole ring and the main chain carbonyl oxygen of Gly473gp120 creates a 4 Å shift (black arrow; C-C distance) of the gp120 main chain to-
ward Trp5445-46m2, and Ile371gp120 adopts a different rotamer to accommodate Trp5445-46m2. (D) Electron density (green mesh;  = 2) for an N-linked glycan 
attached to Asn276gp120. A portion from the final model of the 45-46m2–gp120 complex is superimposed on an Fo-Fc electron density map calculated using 
the initial model before adding the glycan and after several rounds of simulated annealing refinement. (E) Close-up of the Asn276gp120–attached glycan and 
its interactions with the 45-46m2 LC (semitransparent surface). Side chains of Tyr2845-46m2, Trp6545-46m2, Arg6445-46m2, and Tyr8945-46m2 are shown as sticks.
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Variations from a gp120 consensus sequence  
confer resistance to NIH45-46G54W
We next examined the interactions between 45-46m2 and 
gp120 residues within a gp120 consensus sequence identified 
as involved in resistance to NIH45-46G54W (West et al., 2012). 
In most resistant HIV-1 strains, uncommon amino acids replace 
highly conserved residues in the gp120 D and V5 loops, includ-
ing Asn279gp120/Asp279gp120, Asn280gp120 (loop D), Gly458gp120, 
or Gly459gp120 (base of loop V5; hereafter referred to as the 
N/DNGG consensus). The N/DNGG consensus appears in 
96.4, 96.3, 96.4, and 93.0% of 2,869 unique Env sequences 
from the Los Alamos Database for positions 279gp120, 280gp120, 
458gp120, and 459gp120, respectively. Furthermore, YU-2 escape 
mutant viruses isolated from HIV-1YU-2–infected mice that 
were treated with NIH45-46G54W carried mutations within the 
N/DNGG motif (Klein et al., 2012), selectively mutating the 
N/DNGG motif in YU-2 pseudoviruses reduced or com-
pletely prevented neutralization by NIH45-46G54W (West 
a favorable energy change of complex formation of approxi-
mately 3.5 kcal/mol (assuming 15 cal/mol•Å2 of buried 
hydrophobic surface [Vallone et al., 1998]). Although the Fab–
gp120 protein complex was treated with a deglycosidase before 
crystallization, some N-linked glycans remained intact; thus, we 
found extended electron density for six monosaccharides of a 
glycan attached to Asn276gp120 (Fig. 3 D). The 45-46m2 LC 
made extensive contacts with the Asn276gp120–attached glycan, 
and Tyr2845-46m2(LC) was a central component in this interac-
tion through contacts with the first two N-acetylglucosamines 
and the subsequent mannose (Fig. 3 E). Arg6445-46m2(LC), 
Trp6545-46m2(LC), and Tyr8945-46m2(LC) also contributed to the con-
tact surface with the glycan, which consisted of 554 Å2 buried 
surface area (280 Å2 on 45-46m2 and 274 Å2 on the glycan). In-
teractions with the Asn276gp120–attached glycan by an aromatic 
residue in position 65LC rationalize the observation that Trp65LC/ 
Phe65LC are characteristic residues selected for during affinity 
maturation in the LCs of PVL antibodies (West et al., 2012).
Figure 4. SPR comparisons of the binding of gp120 to NIH45-46, NIH4546G54W, and 45-46m2 Fabs. (A) Sensograms (orange curves) were 
recorded for the interactions of injected 93TH057 gp120 produced in insect (Hi5) and mammalian (HEK293) cells over immobilized Fabs derived from the 
indicated antibodies in a twofold dilution series ranging from 500 to 31 nM. Kinetic constants (ka, kd) were derived from globally fitting the association 
and dissociation phases using a 1:1 binding model (black curves) and affinities were calculated as KD = kd/ka. Residual plots (blue) within each sensogram 
describe the fit of the model to the data. Each binding experiment was conducted twice; once using gp120 produced in insect cells and once using gp120 
produced in mammalian cells. (B) SPR measurements of 500 nM injected 93TH057 gp120 over the indicated immobilized Fabs. Each curve was normalized 
to its Rmax. The gray and white shaded areas designate the association and dissociation phases, respectively.
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strains, which is not directly contacted by PVL antibodies but 
that may influence the conformation of the gp120 V5 loop re-
gion (West et al., 2012). With the exception of the Arg456gp120 
mutant, the positions substituted were based upon mutations 
found in YU-2 escape mutants generated in YU-2–infected 
humanized mice in response to treatment with NIH45-46G54W 
(Klein et al., 2012). Unlike NIH45-46G54W, which lost activity 
against most of these mutants (West et al., 2012), 45-46m2 
neutralized all to at least some degree and potently neutralized 
YU-2R456W, YU-2G458D, and YU-2G459D, which partially re-
sisted NIH45-46G54W neutralization (Fig. 6 A). Alterations in 
residues 279gp120 and 280gp120, including an A281T mutation 
that creates a potential N-linked glycosylation site at Asn279gp120, 
were less tolerated by 45-46m2 and resulted in significant re-
ductions in neutralization potencies (Fig. 6 A). However, the 
ability of 45-46m2 to neutralize mutant YU-2 strains that car-
ried changes in the V5 loop (YU-2G458D and YU-2G459D), one of 
which (YU-2G458D) was only weakly sensitive to neutralization 
et al., 2012), and reverting the nonconsensus residues of the 
resistant T278-50 strain to N/DNGG (A279N/E459G) made 
it sensitive to NIH45-46G54W (IC50 = 0.07 µg/ml; unpub-
lished data). Analysis of the 45-46m2–gp120 complex structure 
suggests that most changes to the N/DNGG motif (Fig. 5 A) 
would cause steric constraints for binding of PVL antibodies 
(Fig. 5, B–D); specifically, substituted residues in the N/DNGG 
motif are likely to clash with Trp10245-46m2(HC) and Trp4745-46m2(HC) 
(Fig. 5, B and D), leading to suboptimal or completely abro-
gated binding. Other residues that may be affected by N/DNGG 
motif alterations include Tyr10045-46m2(HC) and Tyr8945-46m2(LC) 
(Fig. 5 E).
To examine the effects of mutations within the N/DNGG 
motif on neutralization by 45-46m2, we used modified YU-2 
pseudoviruses each including a substitution in a N/DNGG 
consensus residue (Fig. 6 A). We also generated a YU-2 strain 
(YU-2R456W) with a mutation in Arg456gp120, a highly con-
served (95%) residue mutated in five NIH45-46G54W–resistant 
Figure 5. Steric constraints associated with the 
gp120 N/DNGG motif. (A) Overview of loop D (green) and 
the V5 loop (magenta) of gp120 (gray) interacting with the 
surface of the 45-46m2 HC (cyan) and LC (blue). The CD4-
binding loop of gp120 is shown in orange. (B) gp120 V5 
loop region showing Gly458gp120 and Gly459gp120 with over-
laid prediction of the consequences of aspartic acid substi-
tutions at these positions (Asp458gp120 and Asp459gp120; pink 
sticks). Both aspartic acids could clash with Trp4745-46m2(HC). 
(C) Asn279gp120 and Asn280gp120 (sticks and semitranspar-
ent spheres) interactions with 45-46m2. A hydrogen bond 
(orange dashed line) between Asn279gp120 and the nitrogen 
atom of the Trp10245-46m2(HC) indole ring is shown.  
(D) Possible steric clashes between a lysine or a tyrosine in 
gp120 positions 279 and 280 (pink) and Trp10245-46m2(HC) 
and Trp4745-46m2(HC). (E) Stereo image showing modeled 
substitutions in the gp120 N/DNGG consensus sequence 
(Lys279gp120, Tyr280gp120, Asp458gp120, and Asp459gp120) at  
the interface with 45-46m2. Tyr10045-46m2 HC and Tyr8945-46m2 LC,  
which may impose steric constraints for the binding of 
gp120s with nonconsensus substitutions, are shown to-
gether with Trp10245-46m2 HC and Trp4745-46m2 HC.
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a previously described in vitro assay (Sather et al., 2012) to 
compare the relative fitness of YU-2 mutants that either in-
cluded (YU-2A281T) or did not include (YU-2 WT, YU-2N279K, 
and YU-2N280D) a potential N-linked glycosylation site 
(Asn279gp120–X–Ser/Thr281gp120; Fig. 8 A). Although infec-
tious, YU-2A281T exhibited a disrupted replication profile relative 
to the other viruses (Fig. 8 B), suggesting a fitness cost asso-
ciated with an Asn279gp120–attached glycan. Consistent with 
this suggestion, only three strains in the Los Alamos Database 
carry a potential N-linked glycosylation site at Asn279gp120, 
all with low predicted glycosylation potentials (Fig. 8 A and 
below). In addition, unlike the curves for other YU-2 variants, 
the in vitro neutralization curves for YU-2A281T saturated at 
50%, suggesting the existence of heterogeneous viral popu-
lations resulting from incomplete incorporation of N-linked 
glycan at Asn279gp120 (Fig. 7 B and Fig. 8 C).
Available structural information about CD4 binding to 
gp120 can be used to rationalize why the viral replication 
profiles of the YU-2A281T mutant were retarded compared with 
YU-2 WT (Fig. 8 B). The N-linked glycan attached to Asn279gp120 
that was introduced by the A281Tgp120 substitution is predicted 
to exert a fitness cost for HIV-1 by partially blocking the 
CD4bs. Indeed if there was not a fitness cost associated with 
having a glycan at residue 279, one would not expect the 
highly correlated amino acid distribution at sites 279 and 281 
observed in the Los Alamos database. Specifically, residue 
279gp120 is usually Asn (51%) or Asp (46%), and this preference 
is not clade-specific. Residue 281gp120 is Thr in 11% (n = 
314) of the sequences. However, Thr occurs in only one strain 
(CH080183_e_p1) that includes Asn at 279gp120, a distribu-
tion which has a <1 in 10100 chance of occurring randomly 
(Fisher Exact test). Furthermore the middle residue of the po-
tential N-linked glycosylation sequence in this strain is pro-
line, which would prevent attachment of an N-glycan to 
by NIH45-46G54W, indicates that the favorable interaction 
of 45-46m2 with the Asn276gp120-linked glycan can effectively 
compensate for the loss of an optimal interaction in the vicinity 
of V5gp120 even though the 45-46m2 substitution makes no 
direct contacts to this region. Nonetheless, when evaluated 
against natural HIV-1 isolates, NIHG45-46G54W–resistant strains 
that carried a nonconsensus N/DNGG motif were also resis-
tant to 45-46m2 (Fig. 1 C, blue highlighted strains).
Targeting emerging escape mutants
To further improve the potency of 45-46m2 against escape mu-
tants in general and against nonconsensus N/DNGG motifs in 
particular, we created 24 antibody mutants designed to reduce 
steric clashes between 45-46m2 and substituted residues in the 
gp120 N/DNGG motif (Fig. 1 A). The neutralization potencies 
of the new mutant antibodies were evaluated against the panel of 
YU-2 mutants (Figs. 6 and 7 A). Modifying critical somati-
cally mutated residues in PVL antibodies (Trp10245-46m2(HC), 
Tyr10045-46m2(HC), and Tyr8945-46m2(LC); West et al., 2012) to cre-
ate mutants 45-46m4, m5, m6, m16, m17, m18, m20, m21, 
m22, m23, m29, m30, m31, m32, m34, m35, and m36 did not 
improve the neutralization profiles of the antibodies (Fig. 6). 
However, replacing the highly conserved Trp4745-46m2(HC)  
(a germline residue) with different smaller amino acids resulted 
in antibodies capable of neutralizing YU-2N279K, YU-2N280D, and 
YU-2N280Y (Fig. 7, A and B). These mutants, 45-46m7, 45-46m25, 
and 45-46m28 (45-46m2 + HC mutations W47V, W47I, and 
W47T, respectively), effectively neutralized all YU-2 mutants 
with the exception of YU-2A281T, which included a newly in-
troduced potential N-linked glycosylation site at Asn279gp120.
Fitness cost associated with a glycan at Asn279gp120
To explore the effects of the A281Tgp120 mutation that ab-
rogated neutralization of the 45-46m antibodies, we used 
Figure 6. Neutralization of YU-2 mutant strains by 45-46m antibodies. Mean IC50 values (µg/ml) derived from in vitro neutralization assays for 
45-4m antibodies against YU-2 mutants. Three or more independent neutralization assays were performed for each mutant.
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(Fig. 8 A) using the NetNGlyc 1.0 Server indicates no glyco-
sylation potential (strains CY122 and U14842) or a very low 
potential (strain 99CMA121) for Asn279gp120. The YU-2A281S 
Asn279gp120. Additionally, of the 39 strains with Ser281gp120, 
only three have Asn279gp120 (CY122, 99CMA121, and U14842). 
An analysis of the glycosylation potential of these three strains 
Figure 7. Neutralization of YU-2 mutant strains by selected 45-46m antibodies. (A) IC50 values (µg/ml) derived from in vitro neutralization as-
says for selected 45-4m antibodies against YU-2 mutant strains. Five independent neutralization assays were performed for each mutant. (B) Neutraliza-
tion curves for selected YU-2 mutant strains. Error bars represent standard deviation from the mean.
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45-46m28 effectively neutralized YU-2 N/DNGG consen-
sus variants, but these antibodies and a 45-46m2/45-46m7 
combination did not neutralize consensus variant strains that 
were resistant to 45-46m2 (Tables S1, S2, and S4). These re-
sults suggest that changing Trp4745-46m2(HC) to a smaller amino 
acid can only partially alleviate steric constraints associated 
with PVL antibody binding to an N/DNGG consensus vari-
ant. Thus, effective neutralization by 45-46m7, 45-46m25, 
and 45-46m28 of escape mutants that use non-N/DNGG 
consensus residues is likely only when the parent viral strain 
is sensitive to a PVL antibody. However, given the broad 
neutralization profiles of parental PVL antibodies (West et al., 
2012), strains resistant to parental PVLs and to 45-46m7, 
45-46m25, and 45-46m28 as a result of changes in the gp120 
N/DNGG consensus sequence are likely to be rare. Addition 
of 10–1074, a more potent clonal variant of PGT121 (Walker 
et al., 2011) that recognizes a carbohydrate-dependent ep-
itope associated with the gp120 V3 loop (Mouquet et al., 2012), 
or PG9, a carbohydrate-dependent bNAb recognizing a V1/V2 
epitope (Walker et al., 2009), into the mixture resulted in 
neutralization of almost all resistant strains (Table S4).
Antibodies can drive HIV-1 mutation or even control viral 
replication in humanized mice (Klein et al., 2012), offering 
the opportunity to examine HIV-1 escape mutations that arise 
in response to treatment with selected bNAbs. We compared 
escape mutations in HIV-1YU-2 that arose in response to a 
45-46m2/45-46m7 combination versus monotherapy with 
mutant has a higher glycosylation potential at Asn279gp120 
compared with the 99CMA121 strain (0.5402 vs. 0.5188; 
Fig. 8 A), but unlike YU-2A281T, the YU-2A281S mutant was 
neutralized well (Fig. 8 C), suggesting that an N-glycan was 
not incorporated at Asn279gp120 despite the N-X-S motif.
Considering the close contacts that 45-46m2 makes with 
Asn279gp120 (Fig. 5 C), an N-linked glycan attached to 
Asn279gp120 would most likely prevent 45-46m2 binding to 
gp120s on spike trimers, resulting in resistance to neutraliza-
tion. The saturation of the YU-2A281T neutralization curves at 
values <100% (Fig. 7 B and Fig. 8 C) is consistent with both 
a sensitive and a resistant population of virions, suggesting only 
partial incorporation of N-linked glycan attached to Asn279gp120. 
Incomplete processing at the level of individual gp120 pro-
tomers would likely give rise to heterogeneously glycosylated 
trimeric Env spikes, i.e., trimers that were fully, partially, or not 
glycosylated at residue 279. At the population level, the sensi-
tivity of YU-2A281T viruses to 45-46m2-like antibodies would 
vary according to the Env composition of each virus, thereby 
giving rise to both resistant and sensitive virions within the 
set of YU-2A281T viruses.
Combinations of antibodies improve anti–HIV-1  
activity in vitro and in vivo
We next evaluated the breadth and potencies of selected anti-
bodies alone and in combination using the 118 strain cross-
clade virus panel (Tables S1 and S2). 45-46m7, 45-46m25, and 
Figure 8. Analysis of the potential N-linked glycosylation site at Asn279gp120. (A) Sequence alignment of YU-2, the two YU-2 Ala281gp120 mutants, and the 
three known HIV strains with a potential N-linked glycosylation site at Asn279gp120. The glycosylation potential for Asn279gp120 was calculated for each strain using 
NetNGlyc 1.0 Server. A glycosylation site is predicted (red highlighted numbers) if the glycosylation potential is ≥0.5. (B) Replication profiles of YU-2 escape mutants. 
Two independent experiments compared the replication of various YU-2 escape mutants to YU-2 WT in PBMC cell culture. Levels of virus in the supernatant were 
determined by measuring p24 levels at various time points after inoculation, and each value represents the mean of two replicates each from two independent 
experiments. (C) Neutralization curves for 45-46m2 and 45-46m7 against YU-2A281T and YU-2A281S. The curves for YU-2A281T were derived using an extended concen-
tration series. Error bars represent standard deviation from the mean. (D) Neutralization of A281T-associated mutations affecting the Asn276gp120-linked glycan.
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not sufficient. Consistent with this suggestion, the in vitro IC50 
values for 45-46m2 and 45-46m7 against loop D variants were 
>0.1 µg/ml whereas the IC50 values for V5 variants were 
<0.01 µg/ml (Fig. 7 A).
The predominant escape mutant found in viruses isolated 
from the 45-46m2/45-46m7–treated mice was A281Tgp120, 
a substitution which introduces a potential N-linked glycosyl-
ation site at Asn279gp120 and results in a less fit virus (Fig. 8 B). 
In the context of an Asn279gp120-linked glycan, compensa-
tory mutations to remove the potential N-linked glycosyl-
ation site at Asn276gp120 were selected (Fig. 9 C, Fig. 10 A, and 
Table S5 A). Specifically, attachment of an N-linked glycan to 
Asn276gp120 was prevented by altering the asparagine (N276D 
and N276S) or the final residue (T278A) in the Asn-X-Ser/
Thr potential N-linked glycosylation sequence motif. We 
speculate that a glycan attached to Asn279gp120 in a gp120 lack-
ing Asn276gp120-attached glycan could be pushed toward the 
NIH45-46G54W. Treatment with 45-46m2/45-46m7 resulted 
in a significant initial drop in viremia by 7 d (Fig. 9, A and B, 
P = 0.0057). Although viremia rebounded to pretreatment 
levels after 21 d in seven of eight mice, the Env sequences 
isolated from the 45-46m2/45-46m7–treated viremic mice 
revealed striking differences compared with viruses isolated 
after escape from NIH45-46G54W monotherapy (Klein et al., 
2012; Fig. 9 C, Fig. 10 A, and Table S5 A). Notably, muta-
tions in the GG portion of the N/DNGG consensus sequence 
(Gly458gp120 and Gly459gp120), which resulted in resistance to 
NIH45-46G54W (Fig. 7 A) and that were isolated after NIH45-
46G54W monotherapy (Klein et al., 2012), were absent (Fig. 9 C; 
Fig. 10 A; Table S5 A). Although effective against potential 
mutations in the V5 region (residues 458gp120 and 459gp120), 
the combination of 45-46m2 and 45-46m7 did not eliminate 
mutations in loop D (residues 279gp120 and 280gp120). This may 
indicate that the antibody concentrations reached in vivo were 
Figure 9. HIV-1 therapy by a combination 
of two (45-46m2 + 45-46m7, labeled 
45-46m2/m7) or three (45-46m2/m7 + 
10–1074) bNAbs in HIV-1YU2–infected 
humanized mice. (A) Viral load. Left panels: 
viral load change from baseline (log10 HIV-1 
RNA copies/ml). Right panels: absolute viral 
load per mouse (RNA copies/ml). Each line 
represents a single mouse. Red arrows indi-
cate start of antibody treatment; green lines, 
geometric mean of untreated mice; red lines, 
geometric mean of antibody treatment group 
indicated. Treatment groups were analyzed in 
parallel and reflect a single experiment com-
prising six control animals (untreated), eight 
mice treated with 45-46m2/m7, and six ani-
mals treated with the combination 45-46m2/
m7 + 10–1074. Similar results were obtained 
for the 45-46m2/m7 group in an independent 
experiment involving six mice (not depicted). 
(B) Mean viral load change (log10 HIV-1 RNA 
copies/ml) from baseline at the indicated 
number of days from start of therapy (mean 
and standard error are shown). Statistical test: 
Kruskal-Wallis test with Dunn’s multiple com-
parison post-hoc test. Asterisks (*, P ≤ 0.05; 
**, P ≤ 0.01) reflect statistically significant 
differences between the treatment groups 
indicated. (C) Pie charts illustrate the distribu-
tion of amino acid changes in gp120 at sites 
targeted by NIH45-46G54W (left; data from 
Klein et al., 2012) versus the 45–46(m2/m7) 
combination (right). Wedge sizes reflect the 
percent of gp120 sequences carrying the 
indicated resistance mutation at the time of 
viral rebound. Center numbers refer to the 
number of mice (left) and the number of 
gp120 sequences (right) for each set of data. 
Mutations listed within the A281T sector of 
the 45-46m2/m7 pie chart reflect compensa-
tory mutations accompanying A281T.
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DISCUSSION
Antibody-based therapies using combinations of bNAbs are a 
promising approach for treating or preventing HIV-1 infec-
tion (Klein et al., 2012), with the best antibody regimen still 
to be devised. The successful use of structure-based design to 
improve NIH45-46 demonstrates that bNAbs, as isolated from 
HIV-1–infected donors (Scheid et al., 2011), are not necessar-
ily optimal in neutralization breadth or potency. Thus, we were 
able to create NIH45-46G54W, which exhibited an overall 10-fold 
increased potency over its parental bNAb by changing only a 
single amino acid (Diskin et al., 2011). Here, we used a com-
bination of structure-based rational design and bioinformatics 
analyses of sequence features of HIV-1 resistance to construct 
further improved versions of NIH45-46G54W, resulting in new 
bNAbs with improved breadth that restrict potential path-
ways for HIV-1 escape by mutation.
One of the new bNAbs, 45-46m2, neutralizes 96–97% of 
HIV-1 strains including VC10042 isolates (Sather et al., 2012) 
and is equivalent or better on its own than a combination of 
VRC01 and PG9 (Doria-Rose et al., 2012). Remarkably, 77% 
of tested viruses were extremely sensitive to 45-46m2, having 
IC50 values at or below 0.1 µg/ml, as compared with 27% of 
viruses neutralized by VRC01 at this IC50 cutoff (Fig. 1 B). 
The crystal structure of 45-46m2 bound to the clade A/E 
93TH057 gp120 revealed that Tyr2845-46m2(LC) makes a favorable 
empty space created by elimination of the Asn276gp120 glycan 
to facilitate binding to CD4. Thus, eliminating the glycan at 
Asn276gp120 could compensate for the otherwise unfavorable 
addition of a glycan to Asn279gp120. The suggestion that muta-
tions to remove an Asn276gp120-linked glycan are compensa-
tory mutations required when an Asn279gp120-linked glycan is 
introduced rather than escape mutations on their own is con-
sistent with potent neutralization of N276S and T278A mu-
tants of YU-2 by NIH45-46G54W, 45-46m2, and 45-46m7 
(Fig. 8 C) and the emergence of N276S and T278A mutations 
only when A281T was present (Fig. 10 A and Table S5 A).
When HIV-1YU2–infected mice were treated with a combi-
nation of 45–46-m2, 45-46m7, and 10–1074 (Mouquet et al., 
2012), we observed control of viremia in all animals that lived 
beyond 20 d after the start of treatment (Fig. 9, A and B). With 
regards to the animal that died before this time, gp120 sequences 
just before its death did not harbor mutations that would indi-
cate escape from either 10–1074 or 45-46m2/m7 (Fig. 10 B and 
Table S5 B). Although some mice had detectable viral loads dur-
ing treatment, we did not find any known escape mutations in 
viruses isolated during treatment for the bNAbs used in the 
treatment mix (Fig. 10 B and Table S5 B). Thus the combina-
tion of 45-46m2 and 45-46m7 effectively reduced the available 
pathways for escape, and the 45-46m2, 45-46m7, and 10–1074 
combination potently treated HIV-1YU-2–infected mice.
Figure 10. Mutation analysis of gp120 sequences during antibody therapy. HIV-1YU2–infected humanized mice were treated with a combination 
of two (45-46m2 + 45-46m7, labeled 45-46m2/m7; A) or three (45-46m2/m7 + 10–1074; B) bNAbs and the sequences of gp120s from escape mutant 
viruses were determined. Individual gp120 nucleotide sequences are represented by horizontal gray bars with silent mutations indicated in green and 
replacement mutations in red. Shaded vertical lines indicated regions that allowed escape from NIH45-46G54W (amino acid positions 280 and 459) and 
from 10–1074 (amino acid position 332). All substitutions are relative to HIV-1YU2 (accession no. M93258) and numbered according to HXB2.
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viremic mice did not include mutations in the GG portion of 
the N/DNGG consensus sequence, whereas viruses including 
these mutations were isolated after NIH45-46G54W monother-
apy (Fig. 9 C, Fig. 10 A, and Table S5 A). Thus, as designed, the 
new bNAbs successfully restricted the number of pathways that 
led to escape from their parental bNAb. Indeed, escape from 
the 45-46m2/45-46m7 combination was mostly limited to 
substitutions involving introduction of a potential N-linked 
glycosylation site at Asn279gp120 and substitutions to compensate 
for the reduced fitness of virions with an Asn279gp120-associated 
glycan (Fig. 9 C). Specifically, the most frequent mutation after 
45-46m2/45-46m7 treatment was A281T, a substitution which 
introduces an Asn279gp120-attached N-linked glycan, and com-
pensatory mutations to remove the glycan at Asn276gp120 in 
order to accommodate the otherwise unfavorable addition of 
carbohydrate at Asn279gp120.
Although we were able to restrict potential pathways for 
HIV-1 escape from bNAbs, these results illustrate the great diffi-
culty of identifying a bNAb or pair of closely related bNAbs 
targeting the same epitope that can eliminate all escape path-
ways. Successful antibody-based therapy strategies may therefore 
require combinations of bNAbs targeting different epitopes. 
Previous results demonstrated viremic control in HIV-1YU-2–
infected humanized mice using a mix of five bNAbs targeting 
four different epitopes on the viral spike (Klein et al., 2012). 
Here, we showed that three antibodies, 45-46m2, 45-46m7, and 
10–1074 (Mouquet et al., 2012), targeting only two epitopes, 
can control viremia in vivo (Fig. 9, A and B); thus, this combina-
tion of bNAbs was able to suppress both the parental viral YU-2 
viral strain and N/DNGG consensus-based escape mutants.
The humanized mice used in these experiments have de-
fective innate and adaptive immunity. For example, they fail 
to make endogenous antibody responses to HIV (Klein et al., 
2012) and T cell responses are difficult to detect (Baenziger et al., 
2006; Manz, 2007). Therefore, HIV-1 infections in these mice 
may be difficult to control in comparison to macaques or 
humans with an intact immune system. However, humans carry 
a higher overall viral load, and are susceptible to infection with 
a diverse group of HIV-1 strains that could make antibody ther-
apy more challenging than the mouse model. Thus, whether 
or not antibody therapy can be effective in humans remains 
to be determined. Nevertheless, the addition of 45-46m2 and 
45-46m7 to a mixture of other bNAbs increases the efficacy 
of antibody-based therapeutics by restricting potential HIV-1 
escape pathways and/or selecting mutant virions with re-
duced fitness.
MATERIALS AND METHODS
Vector construction, protein expression, and protein purification. 
Modifications of NIH45-46 HC and LC genes were made using QuikChange 
Lightning (Agilent Technologies) and verified by DNA sequencing (Eton 
Bioscience). Antibodies were expressed as IgGs using described protocols 
(Diskin et al., 2010). In brief, secreted IgGs from polyethyleneimine (25kD, 
linear; Polysciences)-mediated, transiently transfected HEK293-6E cells 
were captured on protein A or protein G affinity columns (GE Healthcare) 
and eluted in 100 mM citrate, pH 3.0, and 150 mM sodium chloride. Anti-
bodies subsequently used in neutralization assays were dialyzed into 10 mM 
interaction with the Asn276gp120-attached glycan, rationaliz-
ing the observed increase in efficacy compared with NIH45-
46G54W. However, although the Asn276 gp120 glycan is highly 
conserved (a potential N-linked glycosylation site at Asn276gp120 
is found in 94.7% of 4279 sequences in the Los Alamos data-
base), it is not required for the formation of infectious particles; 
thus, virions evolving in the presence of 45-46m2 might in-
clude mutations that result in the loss of this glycan. Because 
45-46m2 is not solely dependent on this interaction for neutral-
ization, the loss of the Asn276gp120 glycan would not necessarily 
lead to resistance to 45-46m2. Indeed, when the Asn276gp120-
attached glycan was eliminated from YU-2 gp120, either by 
mutating the asparagine (N276S) or the threonine (T278A) in 
the Asn-X-Ser/Thr glycosylation motif, 45-46m2 still potently 
neutralized YU-2 (Fig. 8 D), likely due to other favorable in-
teractions with gp120 of 45-46m2 and its parent antibody 
NIH45-46G54W, which lead to potent neutralization of YU-2 
by the NIH45-46G54W. Strains that were resistant to NIH45-
46G54W but sensitive to 45-46m2, such as T250-4 (Tables S1 
and S2), are likely to have a higher dependency on the interac-
tion with the Asn276gp120-linked glycan.
Although 45-46m2 showed improved breadth compared 
with NIH45-46G54W and other bNAbs, it was still unable to 
neutralize natural HIV-1 isolates that included substitutions in 
the N/DNGG consensus sequence within the gp120 D and V5 
loops. This consensus feature was identified by noticing that un-
common amino acids replaced highly conserved (≥93%) resi-
dues in the gp120 D (Asn279gp120/Asp279gp120 and Asn280gp120) 
and V5 (Gly458gp120 and Gly459gp120) loops of most HIV-1 
strains that are resistant to NIH45-46G54W (Diskin et al., 2011; 
West et al., 2012) or arose in YU-2 viruses during in vivo ther-
apy experiments under selective pressure from NIH45-46G54W 
(Fig. 9 C; Klein et al., 2012). By replacing a highly conserved 
germline residue, Trp4745-46m2(HC), with different smaller amino 
acids, we created mutants such as 45-46m7 that neutralized 
YU-2 pseudoviruses with substitutions in the N/DNGG motif 
more effectively than 45-46m2 (Fig. 7 A). However, both 45-
46m2 and 45-46m7 were ineffective against YU-2A281T, a 
mutant which introduced a potential N-linked glycosylation site 
at Asn279gp120. Interestingly, YU-2A281T exhibited a disrupted 
replication profile compared with wild-type YU2 and other 
YU-2 mutants (Fig. 8 B), suggesting a fitness cost associated 
with an Asn279gp120-attached glycan. Decreased fitness of HIV-1 
strains with Asn279gp120-attached glycan is consistent with analy-
ses of gp120 sequences in the Los Alamos database indicating 
that Asn279gp120-attached glycan is rare or nonexistent in natu-
ral HIV-1 strains. Thus, in vivo treatment with 45-46m7 and 
45-46m2 may drive HIV-1 into a mutation pathway that results 
in progressively less fit virions.
To assess mutations in HIV-1 that evolve in response to the 
new bNAbs, we conducted in vivo therapy experiments in 
HIV-1YU-2–infected humanized mice (Fig. 9). Viral escape 
mutants arising in response to a combination of 45-46m2 and 
45-46m7 were compared with previous results for HIV-1YU-2–
infected mice treated with NIH45-46G54W alone (Klein et al., 
2012). Env sequences isolated from 45-46m2/45-46m7–treated 
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equimolar amount of 93TH057 gp120. After concentration using an Amicon 
(Millipore) spin column, the complex was incubated with 40,000 units of 
Endoglycosidase H (NEB) per 2 mg gp120 in the absence of detergents at 37°C 
for 16 h in the manufacturer’s recommended buffer. The complex was fur-
ther purified using Superdex200 (GE Healthcare) SEC in TBS and concen-
trated to OD280 = 9.5. Data for the structure determination were collected 
from rod-like crystals grown in a vapor diffusion sitting drop set at a final 
volume of 2 µl (1:1 protein/reservoir ratio) with 12% (vol/vol) isopropanol, 
10% (wt/vol) polyethylene glycol 10,000 kD, and 0.1 M citrate, pH 5.0, at 
20°C. The crystals were briefly soaked at 30% (vol/vol) isopropanol, 5% glyc-
erol, 10% (wt/vol) polyethylene glycol 10,000 kD, and 0.1 M citrate, pH 5.0, 
before flash cooling using liquid nitrogen.
Data to 2.82 Å resolution were collected from a P212121 45-46m2–
gp120 complex crystal with similar cell dimensions as the NIH45-46–gp120 
crystals (Diskin et al., 2011) at the Stanford Synchrotron Radiation Lightsource 
(SSRL) beamline 12–2 using a Pilatus 6M (Dectris) detector and 0.9537 Å 
radiation (Table S5). Data were indexed, integrated, and scaled using XDS 
(Kabsch, 2010; Table S5). Using Phaser (McCoy et al., 2007) and the NIH45-
46–gp120 complex (PDB: 3U7Y) as a search model, we found a molecular 
replacement solution comprising one 45-46m2 Fab and one gp120 in the 
asymmetric unit. Several rounds of simulated annealing were performed in 
initial refinement cycles to minimize model bias. The structure was refined 
using iterative cycles of refinement using the Phenix crystallography package 
(Adams et al., 2010) and Coot (Emsley et al., 2010) for manual rebuilding. 
To facilitate refinement at 2.82 Å, we restrained the model by using the 
NIH45-46–gp120 structure as a reference and applying secondary structure 
restraints. The final model (Rfree = 23.1%, Rwork = 19.3%) consists of 5,998 
protein atoms, 242 carbohydrate atoms, and 23 water molecules. 95.63, 4.1, 
and 0.26% of the residues are in the favored, allowed, and disallowed re-
gions, respectively, of the Ramachandran plot. The first glutamine of the 
45-46m2 HC was modeled as 5-pyrrolidone-2-carboxylic acid. Disordered 
regions that were not modeled include residues 1–2 and 210 (the C terminus) 
of the 45-46m2 LC, residues 133–136 and 219–221 (the C-terminus) of the 
45-46m2 HC, and residues 302–308 (a short linker substituting for the V3 
loop), residues 397–408 (a total of 6 residues from V4), and the 6x-His tag 
of 93TH057 gp120.
Structures were analyzed and figures were prepared using PyMol 
(Schrödinger). Buried surface areas were was calculated using a 1.4 Å probe 
using Areaimol as implemented in CCP4i package (Collaborative Computa-
tional Project, Number 4, 1994).
SPR measurements. SPR data were collected using a Biacore T200 in-
strument (GE Healthcare). We used primary amine coupling chemistry to 
immobilize 1000 resonance units (RU) of the Fabs of NIH45-46, NIH45-
46G54W, or 45-46m2 in 10 mM acetate, pH 5.0, at a concentration of 0.2 µM 
to a CM5 sensor chip as described in the Biacore manual. Flow channel 1 
was mock coupled and served as a blank subtraction channel. gp120 pro-
tein was injected as a twofold dilution series (500–31.2 nM) at a flow rate of 
80 µl/min at 25°C in 20 mM HEPES, pH 7.0, 150 mM sodium chloride, 
and 0.005% (vol/vol) P20 surfactant, and sensor chips were regenerated using 
10 mM glycine, pH 2.5. A 1:1 binding model was fit to the blank-subtracted 
data using the Biacore analysis software to derive kinetic constants (ka and kd; 
on and off rates) that were subsequently used to calculate affinities (KD; equi-
librium dissociation constant).
In vitro viral fitness assays. Replication experiments were performed 
as described previously (Neumann et al., 2005; Sather et al., 2012) using 
wild type YU-2 and three point mutants in gp120 designated as YU-2N279K, 
YU-2N280D, and YU-2A281T. The entire gp160 portion of each env variant was 
inserted into the TN6 replication competent viral backbone, and each con-
struct was transfected into 293T cells to produce infectious virions. Stimu-
lated PBMCs were prepared from whole human blood by Ficoll gradient 
separation, followed by 72 h of stimulation by culturing in complete RPMI 
containing 2 µg per ml IL-2 and 3 µg/ml phytohemagglutinin (PHA). 15 × 
106 stimulated PBMCs were infected for 3 h with viral inoculum containing 
citrate, pH 3.0, and 150 mM sodium chloride and adjusted to a concentra-
tion of 1 mg/ml. Fab fragments for crystallization and binding assays were 
obtained by digesting IgGs in 20 mM Tris, pH 8.0, and 150 mM sodium 
chloride (TBS) with a 1:100 ratio of papain (Sigma-Aldrich) activated in 
50 mM phosphate, pH 7.0, 2 mM ethylenediaminetetraacetic acid, and 10 mM 
cysteine at 37°C until completion of the cleavage (20–60 min, monitored by 
SDS-PAGE). The Fc was removed by protein A chromatography and Fabs 
were further purified using Superdex 200 (GE Healthcare) 10/300 Size Ex-
clusion Chromatography (SEC).
The clade A/E 93TH057-derived gp120 core (Zhou et al., 2010; a gp120 
construct lacking the V1/V2 and V3 loops) was expressed in insect cells and 
purified using previously described protocols (Diskin et al., 2011). In brief, 
supernatants from baculovirus-infected insect cells were collected, buffer ex-
changed into TBS, and passed through a Ni2+-NTA affinity column (GE 
Healthcare). gp120 was eluted from the column using TBS plus 250 mM 
imidazole and purified using Superdex 200 16/60 SEC (GE Healthcare) in 
TBS supplemented with 0.02% (wt/vol) sodium azide.
In vitro neutralization assays. We used a previously described pseudo-
virus neutralization assay (Montefiori, 2005) to assess the neutralization po-
tencies of the various antibodies against multiple HIV-1 strains. YU-2 escape 
mutant pseudoviruses were generated by cotransfecting HEK293T cells with 
vectors encoding Env and a replication-deficient HIV-1 backbone as previ-
ously described (Montefiori, 2005). Neutralization assays were preformed 
in-house for evaluating antibody mutants against the YU-2 escape mutants 
(Table S1 and Fig. 6) and by the Collaboration for AIDS Vaccine Discovery 
(CAVD) core neutralization facility for testing a subset of the antibodies 
against a large panel of isolates (Tables S2 and S3). Some of the in-house data 
were derived from neutralization assays that were dispensed automatically by 
a Freedom EVO (Tecan) liquid handler (IC50 values derived from manual 
and robotic assays agreed to within two- to fourfold). In all cases, neutraliza-
tion was monitored by the reduction of a Tat-induced reporter gene (luciferase) 
in the presence of a three-or fivefold antibody dilution series (each concen-
tration run in duplicate or triplicate) after a single round of pseudovirus in-
fection in TZM-bl cell line (Montefiori, 2005). Antibodies were incubated 
with 250 viral infectious units at 37°C for 1 h before incubation with the 
reporter cells (10,000 per well) for 48 h. Luciferase levels were measured 
from a cell lysate using BrightGlo (Promega) and a Victor3 luminometer 
(PerkinElmer). Data were fit by Prism (GraphPad Software) using nonlinear 
regression to find the concentration at which 50% inhibition occurred (IC50 
value). For evaluating the neutralization of YU-2 escape mutants, at least two 
independent experiments were performed. Fig. 6 reports mean IC50 values 
for the various 45–46 mutants if 0.1 < (IC501/IC502) < 10. In cases where the 
two IC50 values did not agree, additional experiments were performed. The 
reported IC50 values for NIH45-46G54W, 45-46m2, and 45-46m7 are means 
calculated from at least five independent experiments.
Env plasmids for pseudovirus production were provided by B. Hahn 
(Perelman School of Medicine, University of Pennsylvania Philadelphia, 
PA), F. McCutchan (The Bill and Melinda Gates Foundation, Seattle, WA), 
G. Shaw (Perelman School of Medicine, University of Pennsylvania, Philadel-
phia, PA), D. Montefiori (Duke University Medical Center, Durham, NC), 
M. Thomson (University of Massachusetts, Amherst, MA), J. Overbaugh (Fred 
Hutchinson Cancer Research Center, Seattle, WA), R. Swanstrom (University 
of North Carolina at Chapel Hill, Chapel Hill, NC), L. Morris (Centre for 
HIV and STIs, National Institute for Communicable Diseases of the National 
Health Laboratory Services, Johannesburg, South Africa), J. Kim (University 
College London, London, UK), L. Zhang (School of Medicine, Tsinghua 
University, Tsinghua, China), D. Ellenberger (Centers for Disease Control 
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